BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 25437992)

  • 1. Vemurafenib-associated gingival hyperplasia in patient with metastatic melanoma.
    Mangold AR; Bryce A; Sekulic A
    J Am Acad Dermatol; 2014 Nov; 71(5):e205-6. PubMed ID: 25437992
    [No Abstract]   [Full Text] [Related]  

  • 2. Delayed oral toxicity from long-term vemurafenib therapy.
    Lloyd-Lavery A; Hodgson T; Coupe N; Bond S; Shah K; Espinosa O; Payne MJ; Middleton MR; Matin RN
    Br J Dermatol; 2016 May; 174(5):1159-60. PubMed ID: 26853702
    [No Abstract]   [Full Text] [Related]  

  • 3. Another adverse effect of vemurafenib: Gingival hyperplasia.
    Salman A; Tekin B; Koca S; Akgul Babacan N; Yumuk PF; Ergun T
    J Dermatol; 2016 Jun; 43(6):706-7. PubMed ID: 26703083
    [No Abstract]   [Full Text] [Related]  

  • 4. Vitiligo in 2 patients receiving vemurafenib for metastatic melanoma.
    Alonso-Castro L; Ríos-Buceta L; Vano-Galvan S; Moreno C; Soria-Rivas A; Jaén P
    J Am Acad Dermatol; 2013 Jul; 69(1):e28-9. PubMed ID: 23768302
    [No Abstract]   [Full Text] [Related]  

  • 5. Erythema nodosum in a patient undergoing vemurafenib therapy for metastatic melanoma.
    Degen A; Völker B; Kapp A; Gutzmer R
    Eur J Dermatol; 2013; 23(1):118. PubMed ID: 23419281
    [No Abstract]   [Full Text] [Related]  

  • 6. Multiple white cysts on face and trunk of a melanoma patient treated with vemurafenib.
    Gebhardt C; Staub J; Schmieder A; Goerdt S; Utikal J
    Acta Derm Venereol; 2015 Jan; 95(1):96-7. PubMed ID: 24710689
    [No Abstract]   [Full Text] [Related]  

  • 7. A case of occipital neuralgia in a vemurafenib-treated melanoma patient.
    Hoashi T; Matsumoto N; Serizawa N; Kataoka K; Nako T; Shirakawa N; Matano Y; Funasaka Y; Saeki H
    Int J Dermatol; 2017 Jan; 56(1):e10-e11. PubMed ID: 27653311
    [No Abstract]   [Full Text] [Related]  

  • 8. Vemurafenib (Zelboraf) with longer follow-up. Metastatic melanoma: a few extra months of life, but many adverse effects.
    Prescrire Int; 2015 Apr; 24(159):89-90. PubMed ID: 25941696
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Tinea hidden by a vemurafenib-induced phototoxic reaction in a patient with metastatic melanoma taking dexamethasone.
    Anforth R; Carlos G; Eiris N; Clements A; Fernandez-Peñas P
    Med J Aust; 2015 Jul; 203(1):41-2. PubMed ID: 26126567
    [No Abstract]   [Full Text] [Related]  

  • 10. Unusual complication of vemurafenib treatment of metastatic melanoma: exacerbation of acantholytic dyskeratosis complicated by Kaposi varicelliform eruption.
    Gupta M; Huang V; Linette G; Cornelius L
    Arch Dermatol; 2012 Aug; 148(8):966-8. PubMed ID: 22911209
    [No Abstract]   [Full Text] [Related]  

  • 11. Vemurafenib and cutaneous adverse events--report of five cases.
    Silva Gde B; Mendes AP; de Macedo MP; Pinto CA; Gibbons IL; Duprat Neto JP
    An Bras Dermatol; 2015; 90(3 Suppl 1):242-6. PubMed ID: 26312729
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Vemurafenib sensitivity skin reaction after ipilimumab.
    Harding JJ; Pulitzer M; Chapman PB
    N Engl J Med; 2012 Mar; 366(9):866-8. PubMed ID: 22375995
    [No Abstract]   [Full Text] [Related]  

  • 13. Severe liver and skin toxicity after radiation and vemurafenib in metastatic melanoma.
    Anker CJ; Ribas A; Grossmann AH; Chen X; Narra KK; Akerley W; Andtbacka RH; Noyes RD; Shrieve DC; Grossmann KF
    J Clin Oncol; 2013 Jun; 31(17):e283-7. PubMed ID: 23650406
    [No Abstract]   [Full Text] [Related]  

  • 14. BRAF(V600) mutation levels predict response to vemurafenib in metastatic melanoma.
    Lebbé C; How-Kit A; Battistella M; Sadoux A; Podgorniak MP; Sidina I; Pages C; Roux J; Porcher R; Tost J; Mourah S
    Melanoma Res; 2014 Aug; 24(4):415-8. PubMed ID: 24933605
    [No Abstract]   [Full Text] [Related]  

  • 15. Vemurafenib-Induced Disseminated Intravascular Coagulation in Metastatic Melanoma.
    van den Brom RR; Mäkelburg AB; Schröder CP; de Vries EG; Hospers GA
    J Clin Oncol; 2015 Dec; 33(36):e133-4. PubMed ID: 24778390
    [No Abstract]   [Full Text] [Related]  

  • 16. Vemurafenib-induced eccrine squamous syringometaplasia.
    Lescoat A; Droitcourt C; Stock N; Le Gall F; Dupuy A
    Dermatology; 2013; 226(4):362-4. PubMed ID: 23860306
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Vemurafenib-induced granuloma annulare.
    Lee SB; Weide B; Ugurel S; Mössner R; Enk A; Hassel JC
    J Dtsch Dermatol Ges; 2016 Mar; 14(3):305-8. PubMed ID: 26972200
    [No Abstract]   [Full Text] [Related]  

  • 18. Vemurafenib-induced panniculitis.
    Villani AP; Zaharia D; Dalle S; Depaepe L; Balme B; Thomas L
    Eur J Dermatol; 2013 Apr; 23(2):258-60. PubMed ID: 23567624
    [No Abstract]   [Full Text] [Related]  

  • 19. Uveitic macular oedema after treatment with vemurafenib.
    Fonollosa A; Mesquida M; Adan A
    Acta Ophthalmol; 2015 Dec; 93(8):e686-7. PubMed ID: 25683228
    [No Abstract]   [Full Text] [Related]  

  • 20. Severe pan-uveitis in a patient treated with vemurafenib for metastatic melanoma.
    Wolf SE; Meenken C; Moll AC; Haanen JB; van der Heijden MS
    BMC Cancer; 2013 Dec; 13():561. PubMed ID: 24289205
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.